Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
22.75(c) 22.25(c) 22.45(c) 22.75(c) 23.4(c) Last
37 271 32 704 21 282 84 894 67 573 Volume
+1.11% -2.20% +0.90% +1.34% +2.86% Change
More quotes
Financials (CHF)
Sales 2020 127 M
EBIT 2020 62,8 M
Net income 2020 63,1 M
Finance 2020 125 M
Yield 2020 -
Sales 2021 65,9 M
EBIT 2021 -21,9 M
Net income 2021 -21,6 M
Finance 2021 96,6 M
Yield 2021 -
P/E ratio 2020 8,25x
P/E ratio 2021 -24,2x
EV / Sales2020 3,00x
EV / Sales2021 6,20x
Capitalization 505 M
More Financials
Company
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
02/20MOLECULAR PARTNERS : Announces Newly Nominated Board Members for Upcoming Annual..
PU
02/06MOLECULAR PARTNERS : reports key financials for FY 2019 and corporate highlights..
PU
01/13MOLECULAR PARTNERS : Affimed Announces Appointment of Andreas Harstrick, M.D., a..
AQ
2019ALLERGAN : and Molecular Partners Present Late-Breaking Data from Phase 3 Studie..
AQ
2019ALLERGAN : and Molecular Partners Announce Acceptance of U.S. FDA Biologics Lice..
AQ
2019MOLECULAR PARTNERS : Allergan and Molecular Partners Announce Acceptance of U.S...
PR
2019MOLECULAR PARTNERS : Allergan and Molecular Partners Announce Topline Safety Res..
PR
2018AMGEN : Molecular Partners Form Immuno-Oncology Collaboration
DJ
2018Molecular Partners agrees cancer immunotherapy deal with Amgen
RE
2018Molecular partners and amgen announce strategic collaboration in immuno-oncol..
TE
2018AMGEN : And Molecular Partners Announce Strategic Collaboration In Immuno-Oncolo..
PR
2018Molecular Partners' R&D Day in New York highlights progress of pipeline of DA..
TE
2018Interim management statement q3 2018
TE
2018Drugmakers tout new medicines as eye disease battle intensifies
RE
2018MOLECULAR PARTNERS REPORTS KEY FINAN : Promising MP0250 clinical data in oncolog..
TE
More news
News in other languages on MOLECULAR PARTNERS AG
02/21Morning Briefing - Markt Schweiz
02/20BOURSE ZURICH : le SMI sans direction franche à l'approche de la mi-journée
02/20Principales informations avant-Bourse
02/20Molecular Partners prévoit un triple remplacement au sein de son conseil
02/18Bourse Zurich: pertes stabilisées, Vifor et AMS voués aux gémonies
More news
Analyst Recommendations on MOLECULAR PARTNERS AG
More recommendations
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MOLN | CH0256379097 | MarketScreener
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 33,20  CHF
Last Close Price 23,40  CHF
Spread / Highest target 114%
Spread / Average Target 41,9%
Spread / Lowest Target -5,98%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Michael Tobias Stumpp Chief Operating Officer
Andreas Emmenegger Chief Financial Officer
Daniel Steiner Senior Vice President-Research
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG29.85%517
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB A/S14.61%16 125